Rao J M, Cowie V A, Mathew B
Department of Psychological Medicine, University of Wales College of Medicine, Ely Hospital, Cardiff.
J Ment Defic Res. 1989 Feb;33 ( Pt 1):81-6. doi: 10.1111/j.1365-2788.1989.tb01453.x.
Sixty-seven neuroleptic-mediated mentally handicapped subjects in a hospital were studied to determine the prevalence of Parkinsonian side effects. A Parkinsonism scale was devised and administered. Sixty-one per cent of the sample had mild to moderately severe side effects. Sex, age, cumulative and current chlorpromazine doses, cumulative and current anticholinergic doses and anti-epileptic medication status did not predict the Parkinsonism scores. Overt brain damage was not a predictor. The difference between the neuroleptic medicated group and neuroleptic free matched controls was highly significant indicating that the Parkinsonian type of movement disorder was related to neuroleptic medication.
为确定帕金森氏症副作用的患病率，对一家医院里67名因使用抗精神病药物导致智力障碍的患者进行了研究。设计并实施了一项帕金森氏症量表。61%的样本有轻度至中度严重的副作用。性别、年龄、氯丙嗪的累积剂量和当前剂量、抗胆碱能药物的累积剂量和当前剂量以及抗癫痫药物的使用状况均无法预测帕金森氏症评分。明显的脑损伤也不是一个预测因素。使用抗精神病药物的组与未使用抗精神病药物的匹配对照组之间的差异非常显著，这表明帕金森氏症类型的运动障碍与抗精神病药物治疗有关。
